Treatment with the aldosterone synthase inhibitor lorundrostat significantly decreased automated office systolic blood pressure in adults with uncontrolled hypertension in the phase 2 TARGET-HTN trial.
Aldosterone synthase inhibitor lorundrostat found to safely lower blood pressure in a clinical trial medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Mineralys Therapeutics, Inc. presented final results from the Target-HTN Phase 2 trial of lorundrostat at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, and simultaneously published in the Journal of the American Medical Association (JAMA).
– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure , including an enhanced response in individuals with.
The investigational siRNA therapeutic showed consistent and sustained reductions in systolic blood pressure in a phase 2 study of adults with hypertension.